Pyridostigmine in Heart Failure

Status: Recruiting

Safety Study of Pyridostigmine in Heart Failure (APP-HF)The purpose of the study is to determine whether novel pharmacological strategies can be used to influence heart rate control in patients with heart failure. This study is being run in collaboration with Dr. Stuart Katz from NYU’s Division of Cardiology.

Eligibility: The study is open to people with heart failure between the ages of 21 – 75 years. 

IRB#: 11-00245

Sponsor: National Institutes for Health